CAR T-cell therapies
iconArrow
Product Candidates
Target
Global Rights
Pre-clinical
Phase I
Phase II/III1
BLA/NDA

CT0532

+
Target:
BCMA
Global Rights:

Global3

Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
R/R MM (China)
R/R MM (US, Canada )
R/R MM (IIT)

CT041

+
Target:
Claudin18.2
Global Rights:

Global

Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
GC/GEJ (China)
GC/PC (US, Canada )
PC (China)
GC/GEJ, PC and other GI tumors (IIT)
CT011
+
Target:
GPC3
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
HCC (China)

CT032

+
Target:
CD19
Global Rights:

Global3

Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
B-NHL (China)

CT01804

+
Target:
GPC3
Global Rights:

Global

Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
HCC (IIT)

CT01814

+
Target:
GPC3
Global Rights:

Global

Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
HCC (IIT)

CT05905

+
Target:
BCMA
Global Rights:

Global

Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
R/R MM (IIT)
KJ-C2112
+
Target:
EGFR/EGFRvIII
Global Rights:
Global
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
Glioblastoma

KJ-C1807(CT048)6

+
Target:
Claudin18.2
Global Rights:

Global

Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
GC/GEJ and PC

KJ-C21136

+
Target:
Mesothelin
Global Rights:

Global

Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
Solid tumor

KJ-C21145

+
Target:
Undisclosed
Global Rights:

Global

Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
Solid tumor
mAb
iconArrow
Product Candidates
Target
Global Rights
Pre-clinical
Phase I
Phase II/III1
BLA/NDA

AB011

+
Target:
Claudin18.2
Global Rights:
Pre-clinical
Phase I
Pivotal***
Phase II/III
BLA/NDA
GC/GEJ and PC (China)

1 Phase II trials of some indications are pivotal studies

2 Core Product Candidate

3 Commercial rights in mainland China have been granted to Huadong Medicine (SZ: 000963). Rights in the South Korean market have been licensed out to HK Inno.N (KOSDAQ: 195940)

4 Developed with our sFv-ε-based T-cell therapy

5 Developed with our THANK-uCAR® technology

6 Developed with our CycloCAR® technology

R/R MM: relapsed / refractory multiple myeloma; GC: gastric cancer; GEJ: gastroesophageal junction cancer; PC: pancreatic cancer; B-NHL: B-cell non-Hodgkin lymphoma; HCC: hepatocellular carcinoma